condition found
Features: |
Sulforaphane is an isothiocyanate derived from glucoraphanin, a compound found predominantly in cruciferous vegetables such as broccoli, Brussels sprouts, and cabbage. It is well known for its potent antioxidant and detoxification properties and has gained significant attention for its potential chemopreventive and anticancer effects. Summary 1.primarily attenuates both DNMTs and HDACs, individually suppressing DNA hypermethylation and histones deacetylation, ultimately upregulating NRF2 (best known for NRF2↑) 2.Antioxidant Activity: • Nrf2 activation leads to the upregulation of a host of antioxidant and detoxification enzymes (e.g., glutathione S-transferase, NAD(P)H:quinone oxidoreductase 1, heme oxygenase-1), which in turn decrease oxidative stress and lower ROS levels. 3.Pro-oxidant Effects in Cancer Cells and Under High-Dose Conditions (>=10uM?) • In certain cancer cell types or at higher concentrations, sulforaphane can paradoxically lead to an increase in ROS levels. • The elevated ROS may overwhelm the cancer cells’ antioxidant defenses, leading to oxidative stress–mediated cell death (apoptosis). • This context-dependent pro-oxidant effect has been explored for its potential in selectively targeting cancer cells while leaving normal cells less affected. - Might not be a good candidate for pro-oxidant strategy depending on concentration >10uM?. - Strong Activation of Nrf2 (best known for) at low to moderate concentrations, hence reduces oxidative stress in both cancer and normal cells. - AMPK signaling activated by SFN, high concentrations of ROS are produced - ROS generation also results in depletion of GSH levels - HIF-1α and VEGF inhibitor - Might be effective against cancer stem cells - But I would not combine that with radiation, as Sulforaphane activates the anti-oxidant master regulator of cells. - “I very much agree: Sulforaphane is a very good addition, even more when the choice is an anti-oxidant therapy” - well known as HDAC inhibitor (typically 5-10um concentrations) -A transient decrease in HDAC activity has also been observed in healthy humans 3 h after providing a daily 200 µM SFN dose, resulting in a plasma concentration of SFN metabolites of 0.1–0.2 µM. Dose/Bioavailabilty information: SFN at a daily dose of 2.2 µM/kg body weight, with a mean plasma level of 0.13 µM Sprout 127.6 grams = 205uM±19.9 content yields SFN 0.5 to 2uM in plasma. However, it is important to consider that at lower doses, specifically 2.5 μM, SFN resulted in a slight increase in cell proliferation by 5.18–11.84% within a 6 to 48 h treatment window. -A therapeutic dose starts at approx 60 grams of the sprouts. -100 g of Broccoli sprouts contain about 15–20 mg of sulforaphane –Organic Broccoli Sprout Powder (Health Ranger) – Avmacol® – NanoPSA (a blend of NanoStilbene™ and Broccoli Sprout Extract). - -750 mg Sulforaphane Glucosinolate in Daily One Serving (2 capsules) (30mg Sulforaphane) Total sulforaphane metabolite concentration in plasma was the highest (>2 μM) at 3 h in human subjects who consumed fresh broccoli sprouts (40g) -human studies with broccoli sprouts or extracts report plasma sulforaphane levels in the low micromolar range (typically 1–2 µM) after ingesting realistic, food-based quantities of sprouts (often in the range of 30–50 g of sprouts or a concentrated extract). BroccoSprouts are young broccoli sprouts that have garnered attention because they contain high amounts of glucoraphanin—a precursor molecule to sulforaphane. Studies have shown that broccoli sprouts can have sulforaphane precursor levels (i.e., glucoraphanin levels) that are 10 to 100 times higher than those found in mature broccoli heads. Glucoraphanin content in broccoli sprouts can range anywhere from about 30 to over 100 mg per 100 grams of fresh sprouts. Once activated (e.g., during consumption when myrosinase acts on glucoraphanin), these levels translate into a significant sulforaphane yield, meaning that even a small amount of broccoli sprouts can deliver a potent dose of this bioactive compound. Importantly, glucoraphanin itself is not bioactive. Rather, enzymatic hydrolysis by myrosinase, present in the plant tissue or in the mammalian microbiome, is necessary to form the active component, SFN. - GFN (glucoraphanin) is hydrolyzed in vivo to SFN via the myrosinase, which is present in gut bacteria as well as the plant itself (also in Radish) - Do not cook the vegetables, or if you do add myrosinase back in by adding radish. - mild heat of broccoli (60–70 °C) inactivated ESP and preserved myrosinase and increased SF yield 3–7-fold - chewing of fresh broccoli sprouts increases the interaction of glucosinolates with myrosinase and consequently, increases the bioavailability of SFN in the body -Note half-life 2-3 hrs. BioAv is good (15-80%) but requires myrosinase Pathways: - induce ROS production - ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx, - Lowers AntiOxidant defense in Cancer Cells: NRF2↓(contrary, actually most raises NRF2), TrxR↓**, GSH↓, Catalase↓(contrary), HO1↓(contrary), GPx↓ - Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑, - lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓ - inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, CXCR4↓, α-SMA↓, ERK↓ - reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMTs↓, EZH2↓, P53↑, HSP↓, Sp proteins↓, - cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓, - inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓, - inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, ECAR↓, OXPHOS↓, GRP78↑, GlucoseCon↓ - inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, PDGF↓, EGFR↓, Integrins↓, - inhibits Cancer Stem Cells : CSC↓, Hh↓, GLi↓, GLi1↓, CD133↓, β-catenin↓, sox2↓, notch2↓, nestin↓, OCT4↓, - Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, 5↓, - SREBP (related to cholesterol). - Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective, - Selectivity: Cancer Cells vs Normal Cells |
Source: |
Type: |
Enzymes involved in regulating gene expression by removing acetyl groups from histones, the proteins around which DNA is wrapped. -Many cancers exhibit altered expression levels of HDACs, which can contribute to the dysregulation of genes involved in cell growth, survival, and differentiation. -HDACs can repress the expression of tumor suppressor genes, leading to uncontrolled cell proliferation and survival. This repression can be a key factor in the development and progression of cancer. -HDAC inhibitors (HDACi) have been developed and are being investigated for their ability to reactivate silenced genes, induce cell cycle arrest, and promote apoptosis in cancer cells. -HDAC1, HDAC2): Often overexpressed in various cancers, including breast, prostate, and colorectal cancers. Their overexpression is associated with poor prognosis. -HDAC4, HDAC5): These may have both oncogenic and tumor-suppressive roles depending on the context and cancer type. -While HDACs are not classified as traditional oncogenes, their overexpression and activity can contribute to oncogenic processes. -HDAC inhibitor works by preventing the removal of acetyl groups from histones, thereby modulating gene expression, influencing cell behavior, and potentially reversing aberrant gene silencing seen in various diseases. -HDAC inhibitors can help reactivate these genes, thereby inhibiting growth and inducing apoptosis in cancer cells. |
1433- | Ash,  | SFN,  |   | A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
3175- | Ash,  | SFN,  |   | Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
1435- | GEN,  | SFN,  |   | The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
- | in-vitro, | Pca, | NA |
1730- | SFN,  |   | Sulforaphane: An emergent anti-cancer stem cell agent |
- | Review, | Var, | NA |
1725- | SFN,  |   | Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway |
- | Review, | Var, | NA |
1724- | SFN,  |   | Sulforaphane: A review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials |
- | Review, | Var, | NA |
1722- | SFN,  |   | Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems |
- | Review, | Var, | NA |
3193- | SFN,  |   | Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress |
- | Review, | Var, | NA |
- | in-vitro, | Pca, | PC3 |
2556- | SFN,  |   | The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review |
- | Review, | Var, | NA |
2555- | SFN,  |   | Chemopreventive functions of sulforaphane: A potent inducer of antioxidant enzymes and apoptosis |
- | Review, | Var, | NA |
2554- | SFN,  |   | Sulforaphane (SFN): An Isothiocyanate in a Cancer Chemoprevention Paradigm |
- | Review, | Var, | NA |
1507- | SFN,  |   | Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects |
- | in-vivo, | Colon, | NA | - | Human, | Nor, | NA |
2448- | SFN,  |   | Sulforaphane and bladder cancer: a potential novel antitumor compound |
- | Review, | Bladder, | NA |
1452- | SFN,  |   | Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells |
- | in-vitro, | GC, | AGS |
1458- | SFN,  |   | Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma |
- | Review, | Bladder, | NA |
1454- | SFN,  |   | Absorption and chemopreventive targets of sulforaphane in humans following consumption of broccoli sprouts or a myrosinase-treated broccoli sprout extract |
- | Human, | Nor, | NA |
1453- | SFN,  |   | Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7 |
- | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
1437- | SFN,  |   | Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition |
- | Review, | NA, | NA |
1434- | SFN,  | GEM,  |   | Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity |
- | in-vitro, | CCA, | HuCCT1 | - | in-vitro, | CCA, | HuH28 | - | in-vivo, | NA, | NA |
1430- | SFN,  |   | Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy |
- | Trial, | BC, | NA |
1428- | SFN,  |   | Broccoli or Sulforaphane: Is It the Source or Dose That Matters? |
- | Review, | NA, | NA |
1061- | SFN,  |   | Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors |
- | vitro+vivo, | NA, | NA |
1508- | SFN,  |   | Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment |
- | Review, | Var, | NA |
1502- | SFN,  |   | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
- | Review, | NA, | NA |
1500- | SFN,  |   | A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase |
- | in-vitro, | Nor, | HEK293 | - | in-vitro, | CRC, | HCT116 |
1497- | SFN,  |   | Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells |
- | in-vitro, | Nor, | PrEC | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
1496- | SFN,  | VitD3,  |   | Association between histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human colorectal cancer cells |
- | in-vitro, | CRC, | Caco-2 |
1494- | SFN,  | doxoR,  |   | Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model |
- | in-vivo, | BC, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
1484- | SFN,  |   | Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action |
- | Review, | Var, | NA | - | Review, | AD, | NA |
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:156 Target#:140 State#:% Dir#:%
wNotes=on sortOrder:rid,rpid